Clinical Trials Browser

Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Cholangiocarcinoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Hyper-IgM Immunodeficiency Syndrome

NCT04613674 2024-03-27

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 3 Completed

441 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05143970 2024-03-20

CHANCES

Phase 1 Unknown

27 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT05999149 2024-02-21

BCTOP-T-N01

Phase 3 Recruiting

424 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06165900 2024-01-03

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Phase 2 Recruiting

136 enrolled

Breast

Breast Neoplasms

NCT04681287 2023-09-25

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Phase 2 Unknown

46 enrolled

Breast

HER2 Positive Metastatic Breast Cancer

NCT05862610 2023-07-24

The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC

Phase 2 Not yet recruiting

150 enrolled

Breast

Breast Neoplasms

NCT02679040 2023-07-03

HIST-RIC

Phase 2 Unknown

101 enrolled

Breast

Breast Neoplasms

NCT05840068 2023-05-03

IGF Level in Breast Cancer Patients Treated With Metformin

Phase 4 Completed

107 enrolled

Breast

Breast Neoplasms

NCT00004935 2023-04-18

Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

Phase 3 Terminated

175 enrolled

Breast

Breast Neoplasms

NCT03386162 2022-11-28

SAFIR-PI3K

Phase 2 Terminated

31 enrolled

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT02000596 2022-05-27

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Phase 2 Terminated

2 enrolled 7 charts

Breast

Breast Neoplasms

NCT05346861 2022-04-26

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Phase 3 Unknown

240 enrolled

Breast

Breast Neoplasms

NCT04004910 2022-03-24

A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients

Phase 1/2 Unknown

170 enrolled

Breast

Breast Neoplasms

NCT05253066 2022-02-23

Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

Phase 2/3 Unknown

130 enrolled

Breast

Breast Neoplasms

NCT04143282 2021-12-07

Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment

Phase 2 Completed

250 enrolled

Breast

Breast Neoplasms

NCT02535221 2021-11-29

Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

Phase 3 Recruiting

234 enrolled

Breast

Breast Neoplasms

Clinical Trials

Morpheus-panBC

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

FACT-TN

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

ECLECTIC

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Renaissance

Resilire

NEOLBC

AVR-CHEMO

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

PTX / BC

AREAL

Triple Negative Breast Cancer and Celecoxib. Pilot Study

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

Arsenous Acid for Refractory Triple-Negative Breast Cancer

SENIOR

Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy

Effect of Vitamin D Supplementation on Chemotherapy Side Effects After Adjuvant Chemotherapy for Breast Cancer

Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP

KENDO

Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results

PATRICIA II

Rainbow

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

CHANCES

BCTOP-T-N01

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC

HIST-RIC

IGF Level in Breast Cancer Patients Treated With Metformin

Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

SAFIR-PI3K

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients

Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment

Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer